Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study

BACKGROUND: Efficacy, safety and pharmacokinetics of simeprevir (TMC435), a once-daily, noncovalent, oral hepatitis C virus (HCV) NS3/4A protease inhibitor, was evaluated in combination with peginterferon α-2a/ribavirin (PegIFNα-2a/RBV) for treatment-naïve, HCV genotype 1-infected patients in Japan....

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Hayashi, Norio, Seto, Chiharu, Kato, Mai, Komada, Yuji, Goto, Shoichiro
Format: Artigo
Jezik:Inglês
Izdano: Springer Japan 2013
Teme:
Original Article—LIVER, PANCREAS, AND BILIARY TRACT
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3895197/
https://ncbi.nlm.nih.gov/pubmed/24005956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00535-013-0875-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki